참고문헌
- A.-B. Gutman and T.-F. Yu, Benemid (p-[di-n-propyl-sulfamyl]-benxoic acid) as uricosuric agent in chronic gouty arthritis, Trans. Assoc. Am. Physicians, 64, 279-288 (1951)
- A.- B. Gutman, Uricosuric drugs, with special reference to probenecid and sulfmpyrazone, Adv. Pharmacol., 4, 91-142 (1966) https://doi.org/10.1016/S1054-3589(08)60098-8
- K.-H. Beyer, H.-F. Russo, E.-K. Tillson, A.-K. Miller, W.-F. Verwey and S.-R. Gass, 'Benemid,' p-(di-n-propylsulfamyl)-benzoic acid; its renal affinity and its elimination, Am. J. Physiol., 166, 625-640 (1951)
- W.-P. Boger, F.-W. Pitts and M.-E. Gallagher, Benemid and carinamide: comparison of effect on para-aminosalicylic acid (PAS) plasma concentrations, J. Lab. Clin. Med., 36, 276-282 (1950)
- P.-G. Dayton, T.-F. Yu, W. Chen, L. Berger, L.-A. West and A.-B. Gutman, The physiological dispositon of probenecid, including renal clearance, in man, studied by an improved method for its estimation in biological material, J. Pharmacol. Exp. Ther., 140, 278-286 (1963)
- T.-B. Tjandramaga, S.-A. Cucinell, Z.-H. Israili, J.-M. Perel, P.-G. Dayton, T.-F.Yu and A.-B. Gutman, Observations on the disposition of probenecid in patients receiving allopurinol, Pharmacology, 8, 259-272 (1972)
- Z.-H. Israili, J.-M. Pereel, R.-F. Cunningham, P.-G. Dayton, T.-F. Yu, A.-B. Gutman, K.-R. Long, R.-C. Jr Long and J.-H. Goldstein, Metabolites of probenecid. Chemical, physical, and pharmacological studies, J. Med. Chem., 15, 709-713 (1972) https://doi.org/10.1021/jm00277a004
- A.- M. Guarino, W.-D. Conway and H.-M. Fales, Mass spectral identification of probenecid metabolites in rat bile, Eur. J. Pharmacol., 8, 244-252 (1969) https://doi.org/10.1016/0014-2999(69)90084-3
- R.-F. Cunningham, Z.-H. Israili and P.-G. Dayton, Clinical pharmacokinetics of probenecid, Clin. Pharmacokinet., 6, 135-151 (1981) https://doi.org/10.2165/00003088-198106020-00004
- J.-M. PereI, R.-F. Cunningham, H.-M. Fales and P.-G. Dayton, Identification and renal excretion of probenecid metabolites in man, Life Sci. I., 9, 1337-1343 (1970) https://doi.org/10.1016/0024-3205(70)90041-X
- W.-D. Conway and S. Melethil, Excretion of probenecid and its metabolites in bile and urine of rats, J. Pharm. Sci., 63, 1551-1554 (1974) https://doi.org/10.1002/jps.2600631013
- A.-M. Guarino and L.-S. Schanker, Biliary excretion of probenecid and its glucuronide, Pharmacal. Exp. Ther., 164, 387-395 (1968)
- S.-P. Spina and E.-C. Jr Dillon, Effect of chronic probenecid therapy on cefazolin serum concentrations, Ann. Pharmacather., 37, 621-624 (2003) https://doi.org/10.1345/aph.1C347
- E.-S. Ho, D.-C. Lin, D.-B. Mendel and T. Cihlar, Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1, J. Am. Sac. Nephrol., 11, 383-393 (2000)
- J.-B. Prtcihard and D.-S. Miller, Mechanisms mediating renal secretion of organic anions and cations, Physial. Rev., 73, 765-796 (1993) https://doi.org/10.1152/physrev.1993.73.4.765
- H.-L. McLeod, Clinically relevant drug-drug interactions in oncology. Br. J. Clin. Pharmacal., 45, 539-544 (1998) https://doi.org/10.1046/j.1365-2125.1998.00719.x
- T. Sekine, N. Watanabe, M. Hosoyarnada, Y. Kanai and H. Endou, Expression cloning and characterization of a novel multispecific organic anion transporter J. Biol. Chem., 272, 18526-18529 (1997) https://doi.org/10.1074/jbc.272.30.18526
- Y. Uwai, M. Okuda, K. Takami, Y. Hashimoto and K. Inui, Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney, FEBS. Lett., 438, 321-324 (1998) https://doi.org/10.1016/S0014-5793(98)01328-3
- B. Bannwarth, F. Pehourcq, T. Schaeverbeke and J. Dehais, Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis, Clin. Pharmacakinet., 30, 194-210 (1996) https://doi.org/10.2165/00003088-199630030-00002
- N. Yasui-Furukori, T. Uno, K. Sugawara and T. Tateishi, Different effects of three transporting inhibitors, veraparnil, cimetidine, and probenecid, on fexofenadine pharmacokinetics, Clin. Pharmacal. Ther., 77, 17-23 (2005) https://doi.org/10.1016/j.clpt.2004.08.026
- A. Resetar, D. Minick and T. Spector, Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics, Biachem. Pharmacal., 42, 559-568 (1991) https://doi.org/10.1016/0006-2952(91)90319-Z
- D.-R. Abernethy, D.-J. Greenblatt, B. Ameer and R.-I. Shader, Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation, J. Pharmacal. Exp. Ther., 234, 345-349 (1985)
- R.-K. Verbeeck, Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet., 19, 44-66 (1990) https://doi.org/10.2165/00003088-199019010-00004
- D.-H. Chatfield and J.-N. Green, Disposition and metabolism of benoxaprofen in laboratory animal and man, Xenobiotica., 8, 133-144 (1978) https://doi.org/10.3109/00498257809060392
- A. Rubin, P. Warric, R.-L. Wolen, S.-M. Chemish, A.-S. Ridolfo and C.-M. Gruber Physiological disposition of fenoprofen in Man. III. Metabolism and protein binding of fenoprofen, J. Pharmacol. Exp. Ther., 183, 449-457 (1972)
- L.-M. Fuccela, G.-C. Goldaniga, E. Moro, V. Tamassia, G.-P. Tosolini and G. Valzelli, Fate of analgesic and anti-inflammatory drug K4277 after oral administration to man, Dur. J.Clin.Pharmacol., 6, 256-260 (1973) https://doi.org/10.1007/BF00644742
- R.-C. Luders, M.-B. Maggio-Cavaliere, H. Egger, H.-T.-L. Chemiken, D.-B. Gum and O. Resnick, Disposition of piprofen, a new anti-inflammatory drug, Clin. Pharmacol. Ther., 21, 721-730 (1977) https://doi.org/10.1002/cpt1977216721
- Y.K atoh, Pranoprofen: In Drug disposition, Vol. 1, R. Katoh (Ed.), Seishi Shoin, Tokyo, pp. 223-229 (1984)
- Y. Kato, N. Ariamand H. Nishimine, Studies on antiinflammatory agents XXXII. Absorption, excretion, distribution and metabolism of 2-(5h-[1]benzopyrano(2,3-b] pyridin-7-yl)propionic acid. (Y-8004) in rats and mice, Yakugaku Zasshi, 96, 819-826 (1976) https://doi.org/10.1248/yakushi1947.96.7_819
- I. Yoshio, A. Iwata, M. Isobe, R. Takamatsu and M. Higashi, The pharmacokinetics of pranoprofen in humans, Yakugaku Zasshi, 110, 509-515 (1990) https://doi.org/10.1248/yakushi1947.110.7_509
- T. Imai, T. Nomura and M. Otagiri, Probenecid-induced changes in the clearance of pranoprofen enantiomers, Chirality, 15, 318-323 (2003) https://doi.org/10.1002/chir.10208
- K. Sagara, I. Yamada, Y. Matsuura, M. Kawata and M. Shibata, Gastrointestinal physiology-regulated dogs for bioavailability evaluation of an oral controlled-release dosage form composed of pulsatile release granules, Biol. Pharm. Bull., 19, 1184-1188 (1996) https://doi.org/10.1248/bpb.19.1184
- M.-L. Rocci and W.-J. Juskko, LAGRAN program for area and moments in pharmacokinetic analysis, Comput. Programs Biomed., 16, 203-216 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
- N. Baber, L. Halliday, R. Sibeon, T. Littler and M.-L. Orme, The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study, Clin. Pharmacol. Ther., 24, 298-307 (1978) https://doi.org/10.1002/cpt1978243298